m6A修饰的RIPK4促进上皮性卵巢癌增殖和顺铂耐药
该研究探讨m6A修饰的RIPK4在上皮性卵巢癌中的表达、功能及顺铂耐药机制。通过临床队列、数据库、细胞和动物模型证实RIPK4作为癌基因促进肿瘤增殖和顺铂耐药。机制上METTL3介导m6A修饰,YTHDF1识别修饰位点防止RIPK4 RNA降解,上调RIPK4表达,激活NF-κB,导致肿瘤生长和顺铂耐药。
要点
- RIPK4在上皮性卵巢癌中表达上调,作为癌基因促进肿瘤细胞增殖和顺铂耐药。
- METTL3介导RIPK4 mRNA的m6A修饰,YTHDF1识别该修饰位点防止RIPK4 RNA降解。
- m6A修饰的RIPK4通过激活NF-κB诱导肿瘤生长和顺铂耐药,可能有助于克服化疗耐药。
核心结论
- 本研究揭示m6A修饰的RIPK4诱导顺铂耐药的新机制,可能有助于克服上皮性卵巢癌的化疗耐药。
研究设计与样本
- 在上皮性卵巢癌队列中评估RIPK4表达及其临床病理影响。
- 利用体外和体内模型研究RIPK4的生物学效应。
- 采用RNA m6A定量测定上皮性卵巢癌细胞总m6A水平。
- 使用荧光素酶报告基因、MeRIP-qPCR、RIP-qPCR和放线菌素D实验研究RNA/RNA相互作用及RIPK4 mRNA的m6A修饰。
主要发现
- RIPK4在上皮性卵巢癌中表达上调,在临床、数据库、细胞和动物模型水平作为癌基因促进肿瘤细胞增殖和顺铂耐药。
- METTL3促进m6A修饰,YTHDF1识别特定m6A修饰位点防止RIPK4 RNA降解并上调RIPK4表达。
- RIPK4上调诱导NF-κB激活,在体外和体内导致肿瘤生长和顺铂耐药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cisplatin (DDP)-based chemotherapy is a common chemotherapeutic regimen for the treatment of advanced epithelial ovarian cancer (EOC). However, most patients rapidly develop chemoresistance. N6-methyladenosine (m6A) is a pervasive RNA modification, and its specific role and potential mechanism in the regulation of chemosensitivity in EOC remain unclear. METHODS: The expression of RIPK4 and its clinicopathological impact were evaluated in EOC cohorts. The biological effects of RIPK4 were investigated using in vitro and in vivo models. RNA m6A quantification was used to measure total m6A levels in epithelial ovarian cancer cells. Luciferase reporter, MeRIP-qPCR, RIP-qPCR and actinomycin-D assays were used to investigate RNA/RNA interactions and m6A modification of RIPK4 mRNA. RESULTS: We demonstrated that RIPK4, an upregulated mRNA in EOC, acts as an oncogene in EOC cells by promoting tumor cell proliferation and DDP resistance at the clinical, database, cellular, and animal model levels. Mechanistically, METTL3 facilitates m6A modification, and YTHDF1 recognizes the specific m6A-modified site to prevent RIPK4 RNA degradation and upregulate RIPK4 expression. This induces NF-κB activation, resulting in tumor growth and DDP resistance in vitro and in vivo. CONCLUSIONS: Collectively, the present findings reveal a novel mechanism underlying the induction of DDP resistance by m6A-modified RIPK4, that may contribute to overcoming chemoresistance in EOC.
引用
- Yin X, Zhao S, Zhang M, et al. m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer. Gynecol Oncol. 2023. PMID: 38086167. doi:10.1016/j.ygyno.2023.11.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。